Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823796 | 0.93 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2828040 | 0.91 | MAPT (0.55) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2827702 | 0.90 | MAPT (0.53) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2828235 | 0.90 | MAPT (0.56) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2825724 | 0.90 | MAPT (0.56) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2827930 | 0.89 | ALDH1A1 (0.53) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2825532 | 0.88 | MAPT (0.54) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2829812 | 0.88 | MAPT (0.52) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2825452 | 0.87 | MAPT (0.54) | MAPTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL2825894 | 0.85 | MAPT (0.51) | MAPTSMN1; SMN2LMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851472-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1791543-B1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090005372-A1 | Triazolophthalazines | ALTANA PHARMA AG (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1791543-A2 | TRIAZOLOPHTHALAZINES | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006024640-A2 | TRIAZOLOPHTHALAZINES | ALTANA PHARMA AG (DE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | PDE2A, PDE12, PDE3A | MAPT 3816/4885SMN1; SMN2 2985/4885LMNA 3740/4885 |
| US-20090005372-A1 | Triazolophthalazines | PDE2A, PDE12, PDE3A | MAPT 3816/4885SMN1; SMN2 2985/4885LMNA 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.